These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 31049819)

  • 21. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients.
    Mercier F; Passot G; Villeneuve L; Levine EA; Yonemura Y; Goéré D; Sugarbaker PH; Marolho C; Bartlett DL; Glehen O;
    Ann Surg Oncol; 2018 Apr; 25(4):1094-1100. PubMed ID: 29238881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
    Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
    Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C; Bijelic L; Sugarbaker PH
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: a multicentre Canadian study.
    Jost E; Mack LA; Sideris L; Dube P; Temple W; Bouchard-Fortier A
    Can J Surg; 2020 Feb; 63(1):E71-E79. PubMed ID: 32080999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
    Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
    Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the elderly.
    Tabrizian P; Jibara G; Shrager B; Franssen B; Yang MJ; Sarpel U; Hiotis S; Labow D
    Surg Oncol; 2013 Sep; 22(3):184-9. PubMed ID: 23827047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351
    [No Abstract]   [Full Text] [Related]  

  • 30. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study.
    Goéré D; Souadka A; Faron M; Cloutier AS; Viana B; Honoré C; Dumont F; Elias D
    Ann Surg Oncol; 2015 Sep; 22(9):2958-64. PubMed ID: 25631064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for Managing Intraoperative Discovery of Limited Colorectal Peritoneal Metastases.
    Mariani A; Gelli M; Sourrouille I; Benhaim L; Faron M; Honoré C; Elias D; Goéré D
    Ann Surg Oncol; 2019 May; 26(5):1437-1444. PubMed ID: 30805806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
    Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
    Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution.
    Teo MC; Tan GH; Tham CK; Lim C; Soo KC
    Ann Surg Oncol; 2013 Sep; 20(9):2968-74. PubMed ID: 23504144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Management of Colorectal Peritoneal Carcinomatosis.
    Lee ZJ; Chia SL; Tan G; Soo KC; Teo CCM
    Ann Surg Oncol; 2018 Aug; 25(8):2340-2346. PubMed ID: 29948417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
    Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
    Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer.
    Cornali T; Sammartino P; Kopanakis N; Christopoulou A; Framarino Dei Malatesta M; Efstathiou E; Spagnoli A; Ciardi A; Biacchi D; Spiliotis J
    Ann Surg Oncol; 2018 Mar; 25(3):679-687. PubMed ID: 29282600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P.R.O.P.S. - A novel Pre-Operative Predictive Score for unresectability in patients with colorectal peritoneal metastases being considered for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Yong ZZ; Tan GHC; Shannon N; Chia C; Teo MCC
    World J Surg Oncol; 2019 Aug; 17(1):138. PubMed ID: 31391066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial.
    Glockzin G; Zeman F; Croner RS; Königsrainer A; Pelz J; Ströhlein MA; Rau B; Arnold D; Koller M; Schlitt HJ; Piso P
    Clin Colorectal Cancer; 2018 Dec; 17(4):285-296. PubMed ID: 30131226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: A retrospective cohort study.
    Ye J; Ren Y; Wei Z; Peng J; Chen C; Song W; Tan M; He Y; Yuan Y
    Surg Oncol; 2018 Sep; 27(3):456-461. PubMed ID: 30217302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
    Lee L; Alie-Cusson F; Dubé P; Sideris L
    J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.